Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer

Docetaxel is a third-generation chemotherapeutic drug that is widely used in the treatment of patients with non-small cell lung cancer (NSCLC). However, the majority of patients with NSCLC eventually acquire resistance to the treatment. In the present study, the mechanism of acquired resistance to d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Lett
Main Authors: Chen, Haiyang, Shien, Kazuhiko, Suzawa, Ken, Tsukuda, Kazunori, Tomida, Shuta, Sato, Hiroki, Torigoe, Hidejiro, Watanabe, Mototsugu, Namba, Kei, Yamamoto, Hiromasa, Soh, Junichi, Asano, Hiroaki, Miyoshi, Shinichiro, Toyooka, Shinichi
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5607652/
https://ncbi.nlm.nih.gov/pubmed/28959367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6678
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados